Prana Biotechnology

Feb 6, 2023

Major Players Teva Pharmaceutical Industries, Vertex Pharmaceuticals Incorporated, AmpliPhi Biosciences Corp, Valeant Pharmaceuticals International Inc., Pfizer, Lundbeck, Alnylam Pharmaceuticals, Inc., Prana Biotechnology Ltd., Cortex Pharmaceuticals Inc., GlaxoSmithKline  among other Segmentation Analysis The antipsychotic drugs segment is expected to be the fastest-growing segment in 2022. The drug type segment is antidepressants, antipsychotic drugs, tetrabenazine, tranquilizers, and others. The antipsychotic drugs segment is expected to witness the highest growth rate during the forecast period. Antipsychotic medications that treat Huntington's disease also work through an antidopaminergic mechanism. In Huntington's disease patients, antipsychotic drugs relieve chorea while also reducing mental symptoms, behavioural abnormalities, and cognitive deficits. Ability Haldol (haloperidol) is a popular antipsychotic medication. It has been demonstrated to alleviate chorea symptoms, although it is associated with a number of adverse effects. Atypical antipsychotics, which are antipsychotic medicines of the second generation, are intended to be more tolerable than traditional therapies, with fewer Parkinson's-like side effects. The symptomatic treatment segment is expected to be the fastest-growing segment in 2022. The treatment segment is disease-modifying therapies and symptomatic treatment. The symptomatic treatment segment is expected to witness the highest growth rate during the forecast period. Symptomatic therapeutic development is primarily concerned with motor dysfunction and chorea. Chorea continues to be the most prominent clinical symptom of Huntington's disease, for which the majority of treatment research have been conducted. For example, Neurocrine Biosciences stated in December 2021 that valbenazine dramatically reduced chorea in persons with Huntington's disease in a Phase 3 clinical trial titled-KINECT-HD. Furthermore, a study published in the journal Brain in May 2021 shows that using gene editing therapy in the early stages of disease has the potential to reduce symptom progression. These continuing research are expected to play a critical part in defining this segment's market share in the next years. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the huntington's disease treatment include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North America region witnessed a major share. The active participation of regulatory authorities in the safe and effective approval of human-use products contributes to market income. Sage Therapeutics Inc.'s SAGE-718, a potential treatment for HD, was awarded fast track status by the FDA in September 2021. Furthermore, market participants are broadening the use of their licenced medicines to include HD as an indication. For example, San Diego-based Neurocrine announced plans to broaden the use of Ingrezzia (valbenazine), a medicine first approved by the FDA in 2017 for the treatment of tardive dyskinesia (TD), for the treatment of Chorea in Huntington's disease. In the second half of 2022, the business planned to file a supplemental New Drug Application for this indication. These developments are significantly increasing income in North America. Country Analysis Germany Germany's Huntington’s disease treatment market size was valued at USD 0.75 million in 2022 and is expected to reach USD 1.19 million by 2030, at a CAGR of 6% from 2023 to 2030. Because of population ageing, the prevalence of the targeted population, the emphasis on aesthetic appearance, and the increase of the research base. Whereas a surge in the number of immunocompromised patients is propelling market growth in this area. China China’s Huntington’s disease treatment market size was valued at USD 0.78 million in 2022 and is expected to reach USD 1.26 million by 2030, at a CAGR of 6.2% from 2023 to 2030. Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo for the treatment of HD chorea in China in May 2020. China is the second country to ratify AUSTEDO after the United States. The company's geographical expansion is likely to result in a larger patient base and more revenue. India India's Huntington’s disease treatment market size was valued at USD 0.60 million in 2022 and is expected to reach USD 0.96 million by 2030, at a CAGR of 6.1% from 2023 to 2030. This rise is due to the disease's high burden, rising healthcare costs, technological discoveries, proactive government efforts, and increased patient awareness of Huntington's disease treatment options. H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., for example, are helping to expand the market by developing symptom management options. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of the huntington's disease treatment market is mainly driven by the rising development. Buy Now Full Report @ https://greyviews.com/checkout/536/single_user_license Contact Us Dermatology Devices Market Size By Product (Treatment Devices and Diagnostic Devices), By Application (Vascular & Pigmented Lesion Removal, Hair Removal, Cellulite Reduction, Skin Rejuvenation, Body Contouring & Fat Removal, Acne & Tattoo Removal, Wrinkle Removal & Skin Resurfacing, and Others), By End-User (Clinics, Hospitals, and Others), Regions, Segmentation, and Projection till 2030 Veterinary Imaging Market Size By Equipment (Ultrasound Imaging Systems, Computed Tomography Imaging Systems, Radiography (X-ray) Systems, Video Endoscopy Imaging Systems, Magnetic Resonance Imaging Systems, and Others), By Animal Type (Large Animals, Small Companion Animals, and Others), By Application (Oncology, Orthopedics, Neurology, Cardiology, and Others), By End-User (Reference Laboratories, Hospitals and Others), Regions, Segmentation, and Projection till 2030